Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hodgkin Disease × entinostat × Clear all

Phase

Status

Sponsor Class

NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Carcinoma, Non-Small-Cell Lung 5 Lung Neoplasms 4 Breast Diseases 4 Thoracic Neoplasms 3 Respiratory Tract Neoplasms 3 Neoplasms 3 Lung Diseases 3 Bronchial Neoplasms 3 Neoplasms, Glandular and Epithelial 2 Neoplasms by Histologic Type 2 Melanoma 2 Kidney Neoplasms 2 Endocrine Gland Neoplasms 2 Digestive System Neoplasms 2 Respiratory Tract Diseases 1 Ovarian Neoplasms 1 Ovarian Diseases 1 Neoplasms by Site 1 Hodgkin Disease 1 Fallopian Tube Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Bronchogenic 1 Advanced Breast Cancer 1

Interventions

Brentuximab Vedotin 21 pembrolizumab 11 Nivolumab 8 Vinblastine 6 Doxorubicin 6 Dacarbazine 6 plerixafor 4 fludarabine 4 Cyclophosphamide 4 Azacitidine 4 Melphalan 3 Granulocyte Colony-Stimulating Factor 3 Gemcitabine 3 Filgrastim 3 Etoposide 3 Busulfan 3 Bleomycin 3 pegfilgrastim 2 mocetinostat 2 givinostat hydrochloride 2 givinostat 2 fludarabine phosphate 2 cc-486 2 abexinostat 2 TPI-287 2 Rituximab 2 Panobinostat 2 Mycophenolic Acid 2 Leukapheresis 2 Dexamethasone 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00866333 2019-10-22

ENGAGE-501

Syndax Pharmaceuticals

Phase 2 Terminated

49 enrolled 12 charts

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡